Trial reportPloS one2021
Circulating levels of cell adhesion molecules and risk of cardiovascular events in obstructive sleep apnea.
Trial report in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 14 citations in OpenAlex.
- CPAP may promote an endothelial inflammatory milieu in sleep apnoea after coronary revascularization.EBioMedicine · 2024Trial
- Dynamics in Pro-Inflammatory Cytokines in Response to Hypoglossal Nerve Stimulation in Obstructive Sleep Apnea.Laryngoscope investigative otolaryngology · 2026Article
- Expression of Inflammatory Markers in Ascending Thoracic Aorta in Patients with Obstructive Sleep Apnea.International journal of molecular sciences · 2026Article
- Obstructive Sleep Apneas and Cardiovascular Diseases.Clocks & sleep · 2026Review
- Beyond the Apnea-Hypopnea Index: Circulating Biomarkers and Device-Based Metrics for Cardiometabolic Risk Stratification in Obstructive Sleep Apnea.Journal of clinical medicine · 2026Review
- Evaluation of Circulating Levels of ICAM-1 in Obstructive Sleep Apnea (OSA) Adults: Systematic Review, Meta-Analysis, and Trial Sequential Analysis of Link Between OSA and Cardiovascular Disease.Life (Basel, Switzerland) · 2025Review
- Cell adhesion molecules and incident hypertension in black and white adults: the REGARDS study.Journal of hypertension · 2025Article
- Article
- Does the severity of obstructive sleep apnea increase the risk of cancer? Clues in apnea-hypopnea index and biomarkers.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2024Article
- Obstructive sleep apnea severity, circulating biomarkers, and cancer risk.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2024Article
- Wildfire-related smoke inhalation worsens cardiovascular risk in sleep disrupted rats.Frontiers in environmental health · 2023Article
- Role of precision medicine in obstructive sleep apnoea.BMJ medicine · 2023Review
- Circulating markers of oxidative stress and risk of incident cardiovascular events in obstructive sleep apnea.Sleep and biological rhythms · 2022Article
- Serum VCAM-1 and ICAM-1 measurement assists for MACE risk estimation in ST-segment elevation myocardial infarction patients.Journal of clinical laboratory analysis · 2022Article
- The Association of Oxidative and Antioxidant Potential with Cardiometabolic Risk Profile in the Group of 60- to 65-Year-Old Seniors from Central Poland.Antioxidants (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObstructive sleep apnea (OSA) patients are at increased risk of cardiovascular disease (CVD). Cell adhesion molecules (CAM) are increased in OSA and CAM are also implicated in the development of CVD. RESEARCH QUESTION: Do CAM (ICAM-1, VCAM-1 and E-selectin) have prognostic value in identifying risk of cardiovascular events in OSA? STUDY DESIGN AND
methodsPatients with suspected OSA referred for a polysomnogram provided a fasting blood sample. Plasma levels of ICAM-1, VCAM-1 and E-selectin were determined by multiplex Luminex Assay (Milliporesigma ON, Canada). Cardiovascular events were determined by deterministic linkage to provincial health databases.
results418 patients were included in the analysis. Mostly male (68.2%), mean age of 50.7 yrs, median AHI 16.5 events/hour, and mean BMI of 31.7 kg/m2. 36 cardiovascular events occurred in 8-yrs of follow up. Higher levels of ICAM-1 were associated with developing CVD (HR = 3.65 95% CI 1.40-9.53, 2nd and 3rd tertiles vs. 1st tertile), including in patients with OSA (HR = 3.1 95% CI 1.16-8.25). E-selectin was significantly associated with cardiovascular events in patients with moderate to severe OSA (HR = 3.31 95% CI 0.94-11.72, 2nd and 3rd tertiles vs. 1st tertile) but not in patients without moderate to severe OSA (HR = 0.67 95% CI 0.19-2.38), p-value for interaction = 0.07.
interpretationIn a suspected OSA cohort, patients with higher levels of ICAM-1 (>816 ng/ml) were significantly more likely to experience a cardiovascular event within 8 years after PSG. In moderate to severe OSA patients, a higher E-selectin (>36.4 ng/ml) was significantly associated with cardiovascular events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.